Michel Seymour - Publications, H-index & Citations

Michel Seymour

university of leeds

60H指数

567论文数

2.1W被引数

收录论文 47

发表时间

Corrigendum to “Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population”勘误表：“Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population”

Annals of Oncology

IF65.4

2025-10-10

OAAI

J.F. Seligmann; D. Morton; F. Elliott; K. Handley; R. Gray; M. Seymour; B. Glimelius; L. Magill; C.J.M. Williams; P. Quirke; D. Bottomley; H.M. Wood; K. Murakami; A.D. Beggs; N.P. West

Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population 新辅助FOLFOX联合或不联合帕尼单抗治疗KRAS野生型局部晚期结肠癌患者：基于FOxTROT试验嵌入的II期人群，并采用扩展生物标志物面板的研究结果

ANNALS OF ONCOLOGY

IF65.4

2025-01-01

PREAI

Seligmann, J. F.; Morton, D.; Elliott, F.; Handley, K.; Gray, R.; Seymour, M.; Glimelius, B.; Magill, L.; Williams, C. J. M.; Quirke, P.; Bottomley, D.; Wood, H. M.; Murakami, K.; Beggs, A. D.; West, N. P.

Baseline imaging biomarkers to predict outcomes in locally advanced colon cancer (LACC): Data from the FOxTROT international randomised-controlled trial 基线成像生物标志物预测局部晚期结直肠癌（LACC）预后的研究：FOxTROT国际随机对照试验数据

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Platt, J. R.; Elliott, F.; Quirke, P.; West, N.; Seymour, M. T.; Magill, L.; Handley, K.; Morton, D.; Tolan, D.; Seligmann, J.

An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma

ESMO OPEN

IF8.3

2024-05-01

OAAI

Baxter, M. A.; Spender, L. C.; Cairns, D.; Walsh, S.; Oparka, R.; Porter, R. J.; Bray, S.; Skinner, G.; King, S.; Turbitt, J.; Collinson, D.; Miedzybrodzka, Z. H.; Jellema, G.; Logan, G.; Kennedy, R. D.; Turkington, R. C.; Mclean, M. H.; Swinson, D.; Grabsch, H. I.; Lord, S.; Seymour, M. J.; Hall, P. S.; Petty, R. D.

FOxTROT: Results of embedded phase II evaluating the addition of panitumumab (pan) to neo-adjuvant FOLFOX for patients (pts) with KRAS-wt colon cancer (CC) with extended biomarker panel

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Seligmann, J.; Morton, D.; Seymour, M.; Elliott, F.; Handley, K.; Glimelius, B.; Williams, C.; Hemmings, G.; Bottomley, D.; Gray, R.; Quirke, P.; Magill, L.; Beggs, A. D.; West, N.

Monitoring for micronutrient deficiency after bariatric surgery-what is the risk?

European Journal of Clinical Nutrition

IF3.3

2023-08-07

OAAI

Lewis, Carrie-Anne; Osland, Emma J.; de Jersey, Susan; Hopkins, George; Seymour, Matthew; Webb, Lindsey; Chatfield, Mark D.; Hickman, Ingrid J.

FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty

ESMO OPEN

IF8.3

2023-02-01

OAAI

Platt, J. R.; Todd, O. M.; Hall, P.; Craig, Z.; Quyn, A.; Seymour, M.; Braun, M.; Roodhart, J.; Punt, C.; Christou, N.; Taieb, J.; Karoui, M.; Brown, J.; Cairns, D. A.; Morton, D.; Gilbert, A.; Seligmann, J. F.

Prediction of poor response to oxaliplatin by an RNA signature derived and validated in colorectal cancer clinical trials

ANNALS OF ONCOLOGY

IF65.4

2022-09-01

OAAI

Hassanieh, S.; Domingo, E.; Blake, A.; Fisher, D.; Redmond, K. L.; Richman, S. D.; Walker, S. M.; Quirke, P.; Wilson, R. H.; Kennedy, R.; Tomlinson, I.; Kaplan, R. S.; Brown, L.; Dunne, P.; Seymour, M. T.; Morton, D.; Adams, R. A.; West, N.; Maughan, T.

The FOCUS4-N trial results and individual patient data meta-analysis (IPDM) of maintenance therapy versus active monitoring for patients with metastatic colorectal cancer (mCRC)

ANNALS OF ONCOLOGY

IF65.4

2021-09-01

OAAI

Adams, R. A.; Fisher, D. J.; Graham, J.; Seligmann, J.; Seymour, M.; Kaplan, R. S.; Yates, E.; Richman, S.; Quirke, P.; Butler, R.; Brown, E.; Collinson, F.; Falk, S.; Wilson, R.; Brown, L. C.; Maughan, T.

Inhibition of WEE1 is effective in TP53 and RAS mutant metastatic colorectal cancer (mCRC): A randomised phase II trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring

ANNALS OF ONCOLOGY

IF65.4

2021-09-01

OAAI

Seligmann, J.; Fisher, D. J.; Brown, L. C.; Adams, R.; Graham, J.; Quirke, P.; Richman, S.; Butler, R.; Domingo, E.; Blake, A.; Braun, M.; Collinson, F.; Jones, R.; Brown, E.; De Winton, E.; Humphies, T.; Kaplan, R.; Wilson, R.; Seymour, M.; Maughan, T.

Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel 晚期右半结肠癌，左半结肠癌和直肠癌的临床和分子特征以及治疗结果: 帕尼单抗III期试验中1180例患者的数据

ANNALS OF ONCOLOGY

IF65.4

2020-08-01

OAAI

Seligmann, J. F.; Elliott, F.; Richman, S.; Hemmings, G.; Brown, S.; Jacobs, B.; Williams, C.; Tejpar, S.; Barrett, J. H.; Quirke, P.; Seymour, M.

Colorectal cancer peritoneal metastases: Biology, treatment and next steps

EJSO

IF2.9

2020-04-01

OAAI

Baaten, Ilona C. P. A.; West, Nicholas P.; Quyn, Aaron J.; Seymour, Matthew T.; Seligmann, Jenny F.

Intratumoral stromal morphometry predicts disease recurrence but not response to 5-fluorouracilresults from the QUASAR trial of colorectal cancer

HISTOPATHOLOGY

IF4.1

2017-11-27

OAAI

Hutchins, Gordon G. A.; Treanor, Darren; Wright, Alexander; Handley, Kelly; Magill, Laura; Tinkler-Hundal, Emma; Southward, Katie; Seymour, Matthew; Kerr, David; Gray, Richard; Quirke, Philip

Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials 研究BRAF突变晚期结直肠癌的不良预后: 来自2530例患者的随机临床试验分析

ANNALS OF ONCOLOGY

IF65.4

2017-03-01

134

OAAI

Seligmann, J. F.; Fisher, D.; Smith, C. G.; Richman, S. D.; Elliott, F.; Brown, S.; Adams, R.; Maughan, T.; Quirke, P.; Cheadle, J.; Seymour, M.; Middleton, G.

A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)

BRITISH JOURNAL OF CANCER

IF6.8

2017-01-17

OAAI

Hall, P. S.; Lord, S. R.; Collinson, M.; Marshall, H.; Jones, M.; Lowe, C.; Howard, H.; Swinson, D.; Velikova, G.; Anthoney, A.; Roy, R.; Dent, J.; Cheeseman, S.; Last, K.; Seymour, M. T.

A randomised phase II study of perioperative epirubicin, cisplatin and capecitabine (ECX) ± lapatinib for operable, HER-2 positive gastric, oesophagogastric junctional (OGJ) or lower oesophageal adenocarcinoma: Results from the UK MRC ST03 lapatinib feasibility study (ISRCTN 46020948)

ANNALS OF ONCOLOGY

IF65.4

2016-10-01

OAAI

Smyth, E.; Rowley, S.; Allum, W.; Stenning, S.; Wotherspoon, A.; Robb, C.; Grabsch, H.; Alderson, D.; Crosby, T.; Mason, R.; Griffin, M.; Mansoor, W.; Darby, S.; Seymour, M.; Thompson, J.; Sothi, S.; Sumpter, K.; Blazeby, J.; Langley, R.; Cunningham, D.

FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS & NRAS

ANNALS OF ONCOLOGY

IF65.4

2016-10-01

OAAI

Adams, R. A.; Brown, E.; Brown, L.; Butler, R.; Falk, S.; Fisher, D.; Kaplan, R.; Quirke, P.; Richman, S.; Samuel, L.; Seligmann, J.; Seymour, M.; Shiu, K. K.; Wasan, H.; Wilson, R.; Maughan, T.

The prevalence and outcomes of frailty in older cancer patients: a systematic review 老年癌症患者虚弱的患病率和结局: 系统评价

ANNALS OF ONCOLOGY

IF65.4

2015-06-01

692

OAAI

Handforth, C.; Clegg, A.; Young, C.; Simpkins, S.; Seymour, M. T.; Selby, P. J.; Young, J.

Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013

ANNALS OF ONCOLOGY

IF65.4

2015-03-01

315

PREAI

Papamichael, D.; Audisio, R. A.; Glimelius, B.; de Gramont, A.; Glynne-Jones, R.; Haller, D.; Koehne, C. -H.; Rostoft, S.; Lemmens, V.; Mitry, E.; Rutten, H.; Sargent, D.; Sastre, J.; Seymour, M.; Starling, N.; Van Cutsem, E.; Aapro, M.

A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?

BRITISH JOURNAL OF CANCER

IF6.8

2014-04-17

OAAI

Maughan, T. S.; Meade, A. M.; Adams, R. A.; Richman, S. D.; Butler, R.; Fisher, D.; Wilson, R. H.; Jasani, B.; Taylor, G. R.; Williams, G. T.; Sampson, J. R.; Seymour, M. T.; Nichols, L. L.; Kenny, S. L.; Nelson, A.; Sampson, C. M.; Hodgkinson, E.; Bridgewater, J. A.; Furniss, D. L.; Roy, R.; Pope, M. J.; Pope, J. K.; Parmar, M.; Quirke, P.; Kaplan, R.

研究方向